Insider · CIK 0001758507
Maximo F Nougues
Files at PBYI (PUMA BIOTECHNOLOGY, INC.). First filing Jul 10, 2025, latest Jan 8, 2026.
Maximo F Nougues files SEC Form 4 as CFO at PBYI (PUMA BIOTECHNOLOGY, INC.). Since Jul 10, 2025, Maximo F Nougues has reported 0 open-market buys worth $0 and 2 open-market sells worth $98k, the latest filed on Jan 8, 2026.
A track record needs three past buys with six months of prices behind them; Maximo F Nougues has 0, so none is measured yet.
The newest scored trade: sold $64k of PBYI on Jan 6, 2026, filed Jan 8, 2026, scored 25 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $64k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PBYI: PUMA BIOTECHNOLOGY, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | PUMA BIOTECHNOLOGY, INC. | $64k 10,945 shares | -5% | +114% from low-5% from high | |
| 23Weak | PUMA BIOTECHNOLOGY, INC. | $34k 9,522 shares | -4% | +48% from low-4% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 7, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | 6,405 0.01% of outstanding | $38k | Jan 7, 2026 | $27k |
| Jan 6, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | 4,540 0.01% of outstanding | $27k | Jan 6, 2026 | none |
| Jul 9, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | 3,935 0.01% of outstanding | $14k | Jul 9, 2025 | $20k |
| Jul 8, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | 5,587 0.01% of outstanding | $20k | Jul 8, 2025 | none |
| Jan 2, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | 10,227 0.02% of outstanding | $31k | Jan 2, 2025 | none |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | AGrant or award Common Stock | +46,739 | $0.00 | $0 | 240,023 | Feb 20, 2026 |
| Feb 18, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | AGrant or award Stock Option (Right to Buy)derivative | +66,541 | $0.00 | $0 | 66,541 | Feb 20, 2026 |
| Jan 6, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | SOpen-market sale Common Stock10b5-1 | -4,540 | $5.84 | $27k | 199,689 | Jan 8, 2026 |
| Jan 7, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | SOpen-market sale Common Stock10b5-1 | -6,405 | $5.88 | $38k | 193,284 | Jan 8, 2026 |
| Jul 8, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | SOpen-market sale Common Stock10b5-1 | -5,587 | $3.53 | $20k | 208,164 | Jul 10, 2025 |
| Jul 9, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | SOpen-market sale Common Stock10b5-1 | -3,935 | $3.54 | $14k | 204,229 | Jul 10, 2025 |
Questions about Maximo F Nougues
Answered from the filings on this page, as of the latest one.
Is Maximo F Nougues buying or selling?
In the last 12 months Maximo F Nougues reported 0 open-market buys worth $0 and 1 open-market sell worth $64k on SEC Form 4; the latest was sold $64k of PBYI on Jan 6, 2026. Grants, option exercises and tax withholding are not counted.
How did Maximo F Nougues's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Maximo F Nougues has 0.
Where does Maximo F Nougues file Form 4?
Maximo F Nougues has filed Form 4 at PBYI (PUMA BIOTECHNOLOGY, INC.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.